Circulation Review Time

Circulation was up from 37.8 in 2023 to 38.6 in 2024. That year-over-year rise matters because it suggests the journal held onto its post-pandemic cardiovascular authority rather than slipping back after the 2021 spike.

Three things separate Circulation's review workflow from its two closest competitors, European Heart Journal and JACC.

Format-free first submission. Circulation doesn't require authors to reformat before initial evaluation. You submit the paper in whatever format it currently has, and the editors evaluate it on cardiovascular substance. Reformatting happens only after the paper is invited for revision. This is a real time-saver at the front end, and it also means editors can't use "wrong format" as a soft rejection.

The Clinical Perspective box. This is the single most underestimated part of Circulation's process. Every original research submission must include a short Clinical Perspective with two parts: "What Is New?" and "What Are the Clinical Implications?" Editors read this before anything else. A Clinical Perspective that says something generic like "our findings may have implications for future cardiovascular research" is already losing. The editors want a sentence a cardiologist would repeat to a colleague at a conference.

The current AHA author instructions and article-type guidance reinforce that early filter. Circulation still allows format-free first submission, but it does not relax the requirement to make the clinical consequence legible immediately. That is why the journal can move quickly without feeling administratively shallow.

AHA family triage happens during desk review, not after rejection. At European Heart Journal, a desk rejection is a desk rejection, you resubmit elsewhere yourself. At Circulation, editors actively route papers across the AHA family during triage. A paper that isn't broad enough for the flagship but has genuine cardiovascular merit might get offered a redirect to Circulation Research (IF 16.2), Circulation: Heart Failure, or Circulation: Arrhythmia and Electrophysiology within the same editorial workflow. That's not a consolation prize. Circulation Research is a top-5 cardiovascular journal. The redirect saves you weeks of reformatting and resubmitting.

Circulation sits atop an AHA family that includes Circulation Research (basic cardiovascular), Circulation: Heart Failure, Circulation: Arrhythmia and Electrophysiology, Circulation: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, and Circulation: Genomic and Precision Medicine.

This cascade is worth taking seriously. Circulation Research (IF 16.2) is a top cardiovascular basic science journal. A redirect from the Circulation editorial office often comes with implicit endorsement that speeds up review at the receiving journal.

One tactical point: if your paper is clearly subspecialty (say, a study of left atrial appendage closure outcomes), submitting directly to the relevant specialty title may be faster than submitting to the flagship hoping for a redirect.

Circulation publishes both clinical and translational cardiovascular research, but the editorial balance tilts clinical. Papers that are primarily basic cardiovascular biology (no clinical connection) are usually redirected to Circulation Research. The editorial question is: would a practicing cardiologist change their clinical approach based on this finding?

In practice: a randomized trial of a new anticoagulant strategy is strong Circulation material. A translational biomarker study validated in patient cohorts works if the biomarker could change risk stratification. A mechanistic study of cardiomyocyte calcium handling in a mouse model is Circulation Research territory. An epidemiological cohort study depends on whether the finding is actionable, "exercise prevents heart attacks" won't clear the bar, but identifying a specific modifiable risk factor with clinical implications might.

Days 1-3 (intake): The editorial office confirms your submission is complete. Format-free means this is mostly a check for required elements: manuscript file, Clinical Perspective box, disclosures, data sharing statements. Rarely causes delays.

Days 3-14 (editorial triage): This is where the 17-day median lives. The handling editor reads the Clinical Perspective first, then the abstract, then scans the paper. The question isn't "is this good science?", it's "is this Circulation science?" Papers clearly out of scope get rejected in the first week. Borderline papers take longer because the editor may consult a section editor.

Weeks 2-4 (reviewer recruitment): The hidden bottleneck. Circulation needs 2-3 reviewers who are experts in the specific cardiovascular area AND available within the next month. Niche topics (cardiac amyloidosis imaging, adult congenital heart disease) take longer than mainstream areas (acute coronary syndrome, heart failure).

Weeks 4-8 (peer review): Reviewers typically have 14-21 days. Many request extensions. Circulation reviewers focus heavily on statistical methods, the journal publishes a lot of clinical trials, and the statistical review is rigorous.

Weeks 6-10 (editorial decision): For papers with split opinions, the editor may seek a third review, adding 2-4 weeks. Decision categories: accept (rare on first submission), minor revision, major revision, reject, or reject with redirect to AHA family journal.

Fast desk rejection (1-2 weeks): The cardiovascular significance isn't broad enough for the flagship, or the Clinical Perspective box does not make the consequence concrete quickly enough. Editors may suggest a specialty Circulation title.

AHA family redirect (2-3 weeks): The editors see cardiovascular merit but think a specialty journal is a better fit. This often comes with a recommendation that helps at the receiving journal. Accept the redirect promptly, sitting on it doesn't help.

Review taking 6+ weeks: Normal. Cardiovascular specialists are busy clinician-scientists with patient care responsibilities. The AHA conference season (November) and ACC meeting season (March) slow things down predictably.

Revision focused on clinical implications or statistics: Common. Editors want clinical relevance made explicit, even for translational papers. Statistical revision requests (sensitivity analyses, subgroup analyses, missing data handling) are also frequent, Circulation's statistical review standards are high.

In our pre-submission review work on Circulation submissions, the delays usually start when a paper is clearly respectable but still uncertain about whether the broad cardiology audience is the right audience.

The Clinical Perspective box is accurate but not sharp enough. Editors read that box early, and we see slower files when "What Are the Clinical Implications?" still sounds like a summary instead of a practice-level consequence a cardiologist would remember.

The paper is strong, but the real audience is a subspecialty journal. Circulation can move quickly when the result matters across cardiology. It moves less cleanly when the strongest readership is really heart failure, EP, imaging, or intervention alone.

The statistical case trails the clinical claim. This journal is quick to pressure-test subgroup logic, missing-data handling, and endpoint hierarchy. When the manuscript makes a big clinical claim on a thinner analytical foundation, the review cycle hardens.

We see the fastest positive outcomes when the Clinical Perspective, the primary endpoint framing, and the first figure all point to the same broad cardiovascular consequence. That alignment usually matters more than any notional week count.

Keep follow-ups short: manuscript ID, submission date, single sentence asking about status.

• Circulation journal profile, Manusights internal guide
• Circulation information for authors
• Circulation article types
• Clarivate Journal Citation Reports, 2024 JCR: Circulation IF 38.6, Q1, rank 1/98 Cardiac and Cardiovascular Systems
• AHA journals portfolio